MX2019007002A - Moduladores de linfocitos t reguladores multivalentes. - Google Patents

Moduladores de linfocitos t reguladores multivalentes.

Info

Publication number
MX2019007002A
MX2019007002A MX2019007002A MX2019007002A MX2019007002A MX 2019007002 A MX2019007002 A MX 2019007002A MX 2019007002 A MX2019007002 A MX 2019007002A MX 2019007002 A MX2019007002 A MX 2019007002A MX 2019007002 A MX2019007002 A MX 2019007002A
Authority
MX
Mexico
Prior art keywords
multivalent
regulatory
binding moiety
cell modulators
receptor
Prior art date
Application number
MX2019007002A
Other languages
English (en)
Inventor
Greve Jeffrey
Kim Jungmin
Nagarajan Niranjana
Cho John
Original Assignee
Delinia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delinia Inc filed Critical Delinia Inc
Publication of MX2019007002A publication Critical patent/MX2019007002A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Abstract

La presente descripción proporciona compuestos que contienen una porción de unión al receptor de IL-2 y una porción de unión a ST2. Los métodos descritos en la presente descripción proporcionan un método para el tratamiento contra una afección mediante la administración, a un sujeto que lo necesite, de una cantidad terapéuticamente efectiva de un compuesto que contiene una porción de unión al receptor de IL-2 y una porción de unión a ST2.
MX2019007002A 2016-12-13 2017-12-13 Moduladores de linfocitos t reguladores multivalentes. MX2019007002A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662433533P 2016-12-13 2016-12-13
PCT/US2017/066163 WO2018112069A1 (en) 2016-12-13 2017-12-13 Multivalent regulatory t cell modulators

Publications (1)

Publication Number Publication Date
MX2019007002A true MX2019007002A (es) 2019-08-22

Family

ID=62488540

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019007002A MX2019007002A (es) 2016-12-13 2017-12-13 Moduladores de linfocitos t reguladores multivalentes.
MX2021004007A MX2021004007A (es) 2016-12-13 2019-06-13 Moduladores de linfocitos t reguladores multivalentes.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021004007A MX2021004007A (es) 2016-12-13 2019-06-13 Moduladores de linfocitos t reguladores multivalentes.

Country Status (11)

Country Link
US (2) US10472405B2 (es)
EP (1) EP3554525A4 (es)
JP (1) JP7228515B2 (es)
KR (1) KR20190094222A (es)
CN (1) CN110177564A (es)
AU (1) AU2017378308A1 (es)
BR (1) BR122020025384B1 (es)
CA (1) CA3044416A1 (es)
MX (2) MX2019007002A (es)
RU (1) RU2769871C2 (es)
WO (1) WO2018112069A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3047024B1 (en) 2013-09-20 2019-04-24 University Of Virginia Patent Foundation Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders
WO2018112069A1 (en) 2016-12-13 2018-06-21 Delinia, Inc. Multivalent regulatory t cell modulators
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
MX2019013517A (es) 2017-05-24 2020-08-17 Pandion Operations Inc Inmunotolerancia dirigida.
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
CA3172359A1 (en) 2018-08-06 2020-02-13 Medikine, Inc. Il-2 receptor binding compounds
US20210403579A1 (en) * 2018-10-31 2021-12-30 Delinia, Inc. Multivalent regulatory t cell modulators
US11739146B2 (en) 2019-05-20 2023-08-29 Pandion Operations, Inc. MAdCAM targeted immunotolerance
JP2022536581A (ja) * 2019-06-19 2022-08-18 キュー バイオファーマ， インコーポレイテッド 多量体ｔ細胞調節性ポリペプチド及びその使用方法
CN110642934B (zh) * 2019-09-10 2022-08-23 中国医学科学院北京协和医院 靶向调节t细胞的长效白介素-2及其在治疗自身免疫病中的应用
US11248030B2 (en) 2019-11-05 2022-02-15 Medikine, Inc. Dual IL-2R and IL-7R binding compounds
IL292802A (en) 2019-11-05 2022-07-01 Medikine Inc Compounds that bind to il2 beta gamma c receptors, preparations containing them and their uses
BR112022014401A2 (pt) 2020-02-03 2022-11-16 Medikine Inc Ligante de il-7r-alfa, composto, composição farmacêutica e ácido nucleico
EP4100427A4 (en) 2020-02-03 2024-01-17 Medikine Inc IL-7R??C BINDING COMPOUNDS
WO2023220692A1 (en) * 2022-05-11 2023-11-16 Slate Bio, Inc. Compositions comprising truncated interleukin-33 and interleukin-2

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DZ2788A1 (fr) * 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
NZ517184A (en) * 1999-07-13 2004-02-27 Bolder Biotechnology Inc Immunoglobulin fusion proteins that are cytokines or growth factors joined to an Immunoglobulin domain
JP2007506681A (ja) 2003-09-23 2007-03-22 ピーディーエル バイオファーマ，インコーポレイティド 抗ｉｌ−２受容体抗体による呼吸器疾患の治療
UY34813A (es) * 2012-05-18 2013-11-29 Amgen Inc Proteínas de unión a antígeno dirigidas contra el receptor st2
EP2872170A4 (en) 2012-07-13 2016-06-22 Zymeworks Inc BISPECIFIC ASYMMETRIC HETÉRODIMÈRES COMPRISING ANTI-CD3 RECOMBINANT PRODUCTS
EP2925785A4 (en) * 2012-11-28 2016-11-16 Zymeworks Inc MANIPULATED IMMUNOGLOBULIN HEAVY CHAIN LIGHT CHAIN COUPLES AND USES THEREOF
EP2970486B1 (en) 2013-03-15 2018-05-16 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
EP3047024B1 (en) 2013-09-20 2019-04-24 University Of Virginia Patent Foundation Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders
CA2931114A1 (en) 2014-02-06 2015-08-13 F. Hoffmann-La Roche Ag Interleukin-2 fusion proteins and uses thereof
CA2954847A1 (en) * 2014-07-21 2016-01-28 Jeffrey Greve Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
WO2018112069A1 (en) 2016-12-13 2018-06-21 Delinia, Inc. Multivalent regulatory t cell modulators

Also Published As

Publication number Publication date
BR112019011799A2 (pt) 2019-10-29
KR20190094222A (ko) 2019-08-12
CN110177564A (zh) 2019-08-27
RU2019121902A3 (es) 2021-04-21
RU2019121902A (ru) 2021-01-18
CA3044416A1 (en) 2018-06-21
BR122020025384B1 (pt) 2022-07-12
US11059877B2 (en) 2021-07-13
AU2017378308A1 (en) 2019-06-20
US20180162919A1 (en) 2018-06-14
EP3554525A4 (en) 2020-08-19
MX2021004007A (es) 2021-06-23
JP7228515B2 (ja) 2023-02-24
WO2018112069A1 (en) 2018-06-21
EP3554525A1 (en) 2019-10-23
RU2769871C2 (ru) 2022-04-07
JP2020501550A (ja) 2020-01-23
US10472405B2 (en) 2019-11-12
US20200031897A1 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
MX2021004007A (es) Moduladores de linfocitos t reguladores multivalentes.
MX2021002406A (es) Composiciones farmaceuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofilica.
MX2021005008A (es) Moduladores de celulas t reguladoras multivalentes.
PT3456717T (pt) Derivado de 4,6-diamino-quinolina-3-carbonitrilo como modulador do cancro da tiróide de osaka (cot) para o tratamento de doenças inflamatórias
ECSP18067631A (es) Composiciones que contienen tucaresol o sus análogos
MX2021002900A (es) Composicion con complejos de nanoparticulas/anticuerpos de paclitaxel unidos a albumina para usarse al tratar linfoma.
MX2016016744A (es) Inhibidores de ezh2 para tratar linfomas.
MX2016011898A (es) Composiciones de compuestos selenoorganicos y metodos de uso de los mismos.
MX2015013154A (es) Uso de higado desceluralizado por perfusion para receluralizacion de celulas de islote.
NZ763982A (en) Compositions and methods for modulating complement factor b expression
PH12017500533A1 (en) 1-alkyl-6-oxo-1, 6-dihydropyridin-3-yl compounds and use as sgrm modulators
MX2016004540A (es) Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda).
NZ722600A (en) Methods of treating mild brain injury
MX2016016388A (es) Uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de pulmon de celula no pequeña y/o cancer de pulmon de celula pequeña.
EA201690014A1 (ru) Популяции клеток, способы трансдифференцировки и способы их применения
UY36292A (es) Compuestos de tetrahidroquinolina para su uso como inhibidores de bromodominios
MX2018004296A (es) Combinacion de un agonista selectivo de il-2rbeta y un agonista il-15 de accion prolongada.
AU2017245414A1 (en) The cure for cancer
MX2019012659A (es) Metodos para tratar ateroesclerosis con neutralizadores gamma-cetoaldehido.
MX2018012904A (es) Uso de beta-agonistas del receptor de la hormona tiroidea.
MX2018012900A (es) Uso de beta-agonistas del receptor de la hormona tiroidea.
EP3327051A4 (en) Polymerizable composition containing polymerizable liquid crystal compound, film, and method for producing film
MX2019015273A (es) Moduladores de alfa-sinucleinca.
EP3424896A4 (en) PROCESS FOR PREPARING A LIQUID COMPOSITION WITH MONOETHERATE, LIQUID COMPOSITION AND METHOD FOR PRODUCING A POLYMERIZABLE COMPOUND
MX2018001221A (es) Composicion farmaceutica con estabilidad de almacenamiento mejorada y metodo para prepararla.